Cargando…

Factors Associated With Reduced Efficacy of Sitagliptin Therapy: Analysis of 93 Patients With Type 2 Diabetes Treated for 1.5 Years or Longer

BACKGROUND: Several studies have shown the effectiveness of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for type 2 diabetes, with a hypoglycemic effect being demonstrated both when it is administered alone or in combination with other oral antidiabetic agents. However, there are few reports abo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanamori, Akira, Matsuba, Ikuro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651072/ https://www.ncbi.nlm.nih.gov/pubmed/23671547 http://dx.doi.org/10.4021/jocmr1256w

Ejemplares similares

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus
por: Kubota, Akira, et al.
Publicado: (2011)

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea
por: Kubota, Akira, et al.
Publicado: (2014)

A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes
por: Takai, Masahiko, et al.
Publicado: (2020)

Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes
por: Yuasa, Shouhei, et al.
Publicado: (2016)

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
por: Kubota, Akira, et al.
Publicado: (2012)

Present status of insulin therapy for type 2 diabetes treated by general practitioners and diabetes specialists in Japan: Third report of a cross‐sectional survey of 15,652 patients
por: Arai, Keiko, et al.
Publicado: (2012)

Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study
por: Umezawa, Shinichi, et al.
Publicado: (2015)

Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study
por: Takai, Masahiko, et al.
Publicado: (2019)

Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
por: Kubota, Akira, et al.
Publicado: (2012)

Primary Care-Based Investigation of the Effect of Sitagliptin on Blood Pressure in Hypertensive Patients With Type 2 Diabetes
por: Yuasa, Shouhei, et al.
Publicado: (2017)

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
por: Takeda, Hiroshi, et al.
Publicado: (2019)

Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study
por: Ishikawa, Masashi, et al.
Publicado: (2015)

Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study
por: Takeda, Hiroshi, et al.
Publicado: (2016)

A survey of clinical physician's perceptions of stigma and advocacy in patients with type 2 diabetes in Kanagawa, Japan
por: Matsuzawa, Yoko, et al.
Publicado: (2022)

Sitagliptin-induced pancreatitis – a longer road than expected
por: Nelson, Matthew, et al.
Publicado: (2014)

One year remission of type 1 diabetes mellitus in a patient treated with sitagliptin
por: Lima-Martínez, Marcos M, et al.
Publicado: (2014)

Six-Year Complete Remission of Type-1 Diabetes Mellitus in an Adult Treated With Sitagliptin
por: Benido Silva, Vânia, et al.
Publicado: (2023)

Efficacy and Safety of Sitagliptin in Japanese Patients With Type 2 Diabetes
por: Ohmura, Hirotoshi, et al.
Publicado: (2015)

EXM 93-15
por: Benincasa, G P, et al.
Publicado: (1993)

Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes
por: Kishimoto, Miyako, et al.
Publicado: (2012)

Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
por: Zeng, De-kang, et al.
Publicado: (2019)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes – A renoprotective effect of sitagliptin
por: Narimani, Rouhollah, et al.
Publicado: (2021)

Fasting Insulin Levels and Metabolic Risk Factors in Type 2 Diabetic Patients at the First Visit in Japan: A 10-year, nationwide, observational study (JDDM 28)
por: Matsuba, Ikuro, et al.
Publicado: (2012)

Genome-Wide Transcriptome Analysis in Type 2 Diabetes Patients Treated by Sitagliptin
por: Ma, Rui, et al.
Publicado: (2022)

The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes
por: Kodera, Ryo, et al.
Publicado: (2017)

Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
por: Weinstock, R. S., et al.
Publicado: (2015)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto, Seitaro, et al.
Publicado: (2015)

Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3
por: Pinheiro, Marcelo Maia, et al.
Publicado: (2016)

Neuromodulation Induced by Sitagliptin: A New Strategy for Treating Diabetic Retinopathy
por: Ramos, Hugo, et al.
Publicado: (2021)

Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes
por: Tseng, Chin-Hsiao
Publicado: (2016)

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency
por: Raji, Annaswamy, et al.
Publicado: (2020)

Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus
por: Kim, Soon Ae, et al.
Publicado: (2011)

Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes switched from glinides
por: Tanaka, Tsuyoshi, et al.
Publicado: (2013)

Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus
por: Ballav, Chitrabhanu, et al.
Publicado: (2013)

Efficacy of Initial Basal-Supported Oral Therapy with Sitagliptin in Untreated Type 2 Diabetes
por: Yoshioka, Keiji
Publicado: (2013)

Real-World Clinical Effectiveness and Cost Savings of Liraglutide Versus Sitagliptin in Treating Type 2 Diabetes for 1 and 2 Years
por: Li, Qian, et al.
Publicado: (2018)

Ten-year follow-up of sitagliptin treatment in patients with type 2 diabetes mellitus
por: Hattori, Sachiko
Publicado: (2021)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_a4otnmio8ql22uaua0ubbm41ig